Thu.Jun 13, 2024

article thumbnail

Global health leader critiques ‘ineptitude’ of U.S. response to bird flu outbreak among cows

STAT

LONDON — Seth Berkley, a longtime and widely respected global health leader , said Thursday that it has been “shocking to watch the ineptitude” of the U.S. response to the avian influenza outbreak among dairy cattle , adding his voice to a chorus of critics. In a presentation in London about vaccine development, Berkley, the former CEO of Gavi, the Vaccine Alliance, raised the issue of H5N1 bird flu when discussing whether the world was ready for another pandemic following i

Vaccines 364
article thumbnail

Despite detractors, Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for now

PharmaVoice

Lilly is the latest to approach the coveted Alzheimer’s approval, but a slate of drugmakers are lining up clinical trials in amyloid and tau to take a shot at improving patient outcomes.

130
130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

In dribs and drabs, USDA reports suggest containing bird flu outbreak in dairy cows will be challenging

STAT

The U.S. Department of Agriculture released two reports Thursday that lay out what has been learned about how H5N1 bird flu is moving among dairy cow herds in the United States. The reports do not shed much new light on the situation. Instead, they sum up what is known: that the outbreak was probably the result of a single “spillover” of the virus from wild birds into a dairy herd, likely late last year, and that movement of cows, farmworkers, and shared equipment appears to be res

363
363
article thumbnail

Regenxbio CEO to step down after 15 years

PharmaVoice

Kenneth Mills will become chair of the gene therapy developer's board while Curran Simpson, the current chief operating officer, will take his place as company head.

130
130
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

With placenta-on-a-chip, researchers hope to gauge how drugs and toxins impact pregnancy

STAT

Early in her pregnancy in 2015, Nicole Hashemi wanted to know how much caffeine was safe for her to consume. “I was actually advised not to drink a lot of caffeine,” Hashemi, an associate professor of mechanical engineering at Iowa State University, told STAT. The American College of Obstetrics and Gynecologists, for instance, advises that pregnant people consume no more than 200 milligrams per day  to reduce the risk of miscarriage or preterm birth.

363
363
article thumbnail

Modifier gene therapy – clinical development and manufacturing considerations

European Pharmaceutical Review

Tell us about Ocugen’s lead programme, OCU400. What’s the latest and what’s next? OCU400 is a modifier gene therapy aimed at treating retinitis pigmentosa and Leber congenital amaurosis (LCA). In April 2024, Ocugen received US Food and Drug Administration (FDA) clearance to initiate the Phase III liMeliGhT clinical trial for OCU400 for retinitis pigmentosa.

Immunity 145

More Trending

article thumbnail

EMCrit 377 – Breaking News – The PREOXI Trial changes everything about Preoxygenation for Intubations in the Critically Ill

EMCrit Project

the PREOXI trial validates what I have been saying for 15 years about preoxygenation for the critically ill patient EMCrit Project by Scott Weingart, MD FCCM.

130
130
article thumbnail

STAT+: Europe is set to shake up the way it assesses new medicines. Gene therapy makers are worried

STAT

LONDON — A major shakeup in how the benefits of medicines are assessed in Europe is looming, and developers of treatments like gene therapies are already arguing that what they see as flaws in the new system could entrench the issues they’ve had getting their products to patients. Starting next year, there will be a new, continent-level review of a drug’s effectiveness compared to what else is on the market.

339
339
article thumbnail

Scrub-a-Dub-Dub: FTC is Cleansing the Orange Book of Device Patents

FDA Law Blog: Biosimilars

By Sara W. Koblitz — As we have noted for the last year or so, the FTC has been on a mission to clean up the Orange Book by removing what it deems to be “improper” patents. The FTC has put out policy statements, challenged patent listings, tapped Congress, appeared on talk shows, and filed amicus briefs all in the span of the last 8 months. It seems like all that work is paying off.

Dosage 113
article thumbnail

STAT+: FDA gets pointed input on ‘optimizing’ advisory committee panels

STAT

The day an FDA advisory committee met to weigh the merits of an experimental treatment for amyotrophic lateral sclerosis was one of the worst of Mitze Klingenberg’s life.  Her son Matt had benefited, she said, from an ALS treatment under review for approval by the Food and Drug Administration. However, the expert panel voted against the therapy on that day, Sept. 27, 2023.

article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Launch Excellence: Moments of Truth

pharmaphorum

Explore the key moments of truth in launch excellence for MSLs and commercial teams in this informative white paper. Gain valuable insights and strategies for successful launches.

114
114
article thumbnail

Opinion: What happened to obesity after Chile slew Tony the Tiger?

STAT

“In Sweeping War on Obesity, Chile slays Tony the Tiger.” So read the headline of a front-page story in The New York Times in 2018 on a dramatic step Chile was taking to fight obesity. With some of the highest obesity levels in South America, the country had begun enforcing strict regulations on Frosted Flakes and other foods that exceeded set thresholds for sugar, calories, salt, or saturated fat in 2016.

315
315
article thumbnail

Pfizer shares update on DMD gene therapy clinical trial

Pharmafile

Pfizer has announced an update from its phase 3 randomised, multicentre, double-blind, placebo-controlled CIFFREO trial, which assessed the investigational mini-dystrophin gene therapy, gordadistrogene movaparvovec, in ambulatory patients with Duchenne muscular dystrophy (DMD). The post Pfizer shares update on DMD gene therapy clinical trial appeared first on Pharmafile.

105
105
article thumbnail

Listen: Duchenne gene therapy setback, Alzheimer’s drug endorsement & why a STAT reporter buys weed (for journalism)

STAT

On this week’s episode of “The Readout LOUD,” our STAT colleague Nicholas Florko joins us to explain what it means to be a reporter who writes about the commercial determinants of health. Hint: Florko’s most recent stories focused on weed, vapes and raw milk. And instead of being chained to a desk, he often drives around to convenience stores and buy bad stuff — all in the name of good journalism.

291
291
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Haemophilia drug could reduce treated bleeding episodes

European Pharmaceutical Review

A next-generation FVIIIa mimetic bispecific antibody has demonstrated statistically significant and superior reduction of treated bleeding episodes in haemophilia A, new headline data from a pivotal Phase IIIa trial show. Mim8 was evaluated in participants aged 12 years or older as both a once-weekly and once-monthly treatment versus no prophylaxis treatment and prior coagulation factor prophylaxis treatment.

98
article thumbnail

STAT+: Will Geron be acquired? The long-short view

STAT

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here  to get it delivered every Thursday to their inbox. I’m back from my ASCO-Chicago detour. I missed you all! This week, let’s argue over Geron’s future and consider Candel Therapeutics to illustrate why survival claims from non-randomized studies are too often red flags.

243
243
article thumbnail

Flagship, ProFound set off on obesity drug hunt for Pfizer

pharmaphorum

Pfizer has had some setbacks in its efforts to develop drugs for the lucrative obesity market, but could see its pipeline swell thanks to its $7 billion partnership with venture capital firm Flagship Pioneering. Flagship has just announced that it will work with biotech startup ProFound Therapeutics to find first-in-class protein therapeutics with potential in obesity, confirming this is the first programme in the alliance with Pfizer signed last July.

104
104
article thumbnail

STAT+: Pharmalittle: We’re reading about a Pfizer drug for Duchenne, bird flu vaccines for cows, and more

STAT

Rise and shine, everyone, another busy day is on the way. We can tell because the pace of motor vehicles passing by our window is picking up and the official mascots are busy foraging for snacks on the campus grounds. As for us, we are engaged in the usual ritual of brewing cups of stimulation. Our choice today is strawberry cream. As always, you are invited to join us.

Vaccines 240
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Mahana’s DTx for IBS gets permanent reimbursement in Germany

pharmaphorum

Mahana Therapeutics has granted permanent reimbursement in Germany for its Cara Care digital therapeutic for irritable bowel syndrome

115
115
article thumbnail

With Avidity and Pfizer, gene therapy enters a phase

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Morning, it’s Meghana today! Some gene therapy talk: Pfizer’s gene therapy for Duchenne muscular dystrophy failed in Phase 3, and gene therapy developers say Europe’s looming regulatory changes may endanger such treatments.

article thumbnail

The B2C prescription: Marketing lessons for B2B pharma companies

pharmaphorum

Learn valuable marketing lessons for B2B pharma companies by examining successful strategies used in the B2C prescription market, including over-the-counter (OTC) products and interactions with healthcare professionals (HCPs).

106
106
article thumbnail

China’s Innovent holds potential to change pancreatic cancer treatment with bispecific antibody IBI389: GlobalData

Express Pharma

China-based Innovent Biologics recently presented Phase I study results of its first-in-class anti-CLDN18.2/CD3 bispecific antibody (IBI389) for the treatment of advanced pancreatic cancer at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Preliminary results from the Phase I study (NCT05164458) of IBI389 demonstrated promising efficacy in pancreatic ductal adenocarcinoma (PDAC) and the bispecific antibody is expected to evolve as a promising therapeutic option for PDAC in

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

EMA consolidates guidelines for computerized systems in clinical trials

Outsourcing Pharma

To guide sponsors, investigators, CROs, and other parties in clinical research, the European Medicines Agency (EMA) has consolidated the contemporary requirements for using computerized systems and electronic data in clinical trials.

97
article thumbnail

Suven to acquire controlling stake in Sapala Organics, a CDMO player

Express Pharma

Suven Pharmaceuticals has entered into a definitive agreement for a strategic controlling investment in Sapala Organics, subject to regulatory approvals and conditions. Sapala is a Hyderabad-based CDMO focused on Oligo drugs and nucleic acid building blocks including specialised/modified Amidites and Nucleosides, drug delivery compounds (including GalNAc), Pseudouridine, amongst others.

article thumbnail

Four takeaways from ASCO24

pharmaphorum

Last weekend, editor-in-chief Jonah Comstock attended the annual conference of the American Society of Clinical Oncologists in Chicago, an event renowned for announcing significant advancements in cancer treatment.

101
101
article thumbnail

Pfizer investigational gene therapy for DMD fails in Phase 3 study

Express Pharma

Pfizer announced that CIFFREO, a Phase 3 global, multicentre, randomised, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne muscular dystrophy (DMD) did not meet its primary endpoint of improvement in motor function among boys 4 to 7 years of age treated with the gene therapy compared to placebo.

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

LifeArc funds new projects to address and prevent global threat of dengue fever

Pharma Times

The mosquito-borne viral disease is responsible for an estimated 390 million cases globally

122
122
article thumbnail

Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision

BioPharma Dive

The failure of another trial adds to uncertainty around the benefits of the gene-based treatments, though industry analysts still expect Sarepta’s Elevidys’ to be unaffected.

96
article thumbnail

FDA approves AstraZeneca’s Farxiga for paediatric T2D patients

Pharmaceutical Technology

The US FDA has granted approval for AstraZeneca's Farxiga for paediatric patients aged 10 years and above with type-2 diabetes.

Diabetes 105
article thumbnail

WuXi buoyed as BIOSECURE Act is left out of US spending bill

pharmaphorum

Shares in WuXi Biologics and WuXi AppTec rose after the BIOSECURE Act was omitted from legislation due to be followed up in congress.

109
109
article thumbnail

Alzheon secures $100m to advance Alzheimer’s disease treatment

Pharmaceutical Technology

Alzheon has secured $100m in a Series E funding round to develop and commercialise ALZ-801 for Alzheimer's disease (AD).

98